MSD (UK) Limited, London, United Kingdom.
Merck & Co., Inc., Rahway, NJ, USA.
Future Oncol. 2024;20(35):2723-2735. doi: 10.1080/14796694.2024.2390351. Epub 2024 Oct 7.
Evaluate healthcare resource utilization (HRU) and costs in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who relapsed or are refractory to (R/R) ibrutinib. All-cause and CLL/SLL-related HRU and healthcare costs were evaluated in adult patients with CLL/SLL who received ibrutinib (2/2014-3/2020) as single-agent or combination therapy and discontinued/switched to another antineoplastic agent (R/R) vs. all other (non-R/R) ibrutinib users. Compared with the non-R/R patients (N = 919), R/R patients (N = 207) had higher all-cause HRU (inpatient, outpatient and emergency room visits; rate ratios [95% ]: 1.51 [1.38, 1.65]-1.92 [1.57, 2.37]; all P < 0.001) and healthcare costs ($81,645 vs. $34,717; cost difference [95% CI] = $50,170 [$40,555, $61,383]; P < 0.001). CLL/SLL patients who are R/R to ibrutinib bear a substantial economic burden.
评估慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者在接受伊布替尼（R/R）后发生或难治的医疗资源利用（HRU）和成本。对接受伊布替尼（2014 年 2 月至 2020 年 3 月）单药或联合治疗的 CLL/SLL 成年患者，评估因发生 R/R 而停止/改用其他抗肿瘤药物（R/R）与其他所有（非 R/R）伊布替尼使用者的全因和 CLL/SLL 相关 HRU 和医疗保健费用。与非 R/R 患者（N=919）相比，R/R 患者（N=207）全因 HRU（住院、门诊和急诊就诊）更高（发生率比[95%CI]：1.51[1.38, 1.65]-1.92[1.57, 2.37]；均 P<0.001），医疗保健费用也更高（$81,645 比 $34,717；费用差异[95%CI]=$50,170[$40,555, $61,383]；P<0.001）。伊布替尼治疗发生 R/R 的 CLL/SLL 患者的经济负担沉重。
